What is TG Therapeutics Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. TG Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.96.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, TG Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for TG Therapeutics's Cash-to-Debt or its related term are showing as below:
TGTX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.95 Med: 150.44 Max: No Debt
Current: 1.96
During the past 13 years, TG Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 1.95. And the median was 150.44.
TG Therapeutics Cash-to-Debt Historical Data
The historical data trend for TG Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TG Therapeutics Cash-to-Debt Chart
|
TG Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
3.44 |
14.42 |
3.98 |
1.95 |
1.96 |
|
TG Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
1.95 |
1.29 |
1.33 |
13.72 |
1.96 |
Competitive Comparison of TG Therapeutics's Cash-to-Debt
For the Biotechnology subindustry, TG Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TG Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TG Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where TG Therapeutics's Cash-to-Debt falls into.
TG Therapeutics Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
TG Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
TG Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TG Therapeutics (TG Therapeutics) Business Description
Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Executives
| Laurence N Charney |
director |
MARVEL ENTERTAINMENT, INC., 417 FIFTH AVENUE, NEW YORK NY 10016 |
| Sean A Power |
officer: CFO, Secretary and Treasurer |
787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019 |
| Michael S Weiss |
director, officer: CEO and President |
750 LEXINGTON AVE, NEW YORK NY 10022 |
| Sagar Lonial |
director |
C/O TG THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014 |
| Yann Echelard |
director |
C/O LFB BIOTECHNOLOGIES, S.A.S., 3, AVENUE DES TROPIQUES LES ULIS, COURTABOEUF I0 91958 |
| Ra Capital Management, L.p. |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Kenneth Hoberman |
director |
750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024 |
| Daniel Hume |
director |
3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019 |
| William James Kennedy |
director |
C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989 |
| Ra Capital Healthcare Fund Lp |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Rajeev M. Shah |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Peter Kolchinsky |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Lfb Biotechnologies S.a.s.u. |
10 percent owner |
3 AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91958 |
| Mark Schoenebaum |
director |
787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019 |
| Opus Point Partners, Llc |
10 percent owner |
787 7TH AVENUE, 48TH FLOOR, NEW YORK NY 10019 |
TG Therapeutics (TG Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TGTX has been successfully added to your